Φορτώνει......

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

BACKGROUND: Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking. METHODS: This was a prospective, single-arm phase 3b study...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	BMC Cancer
Κύριοι συγγραφείς:	Heidenreich, Axel, Gillessen, Silke, Heinrich, Daniel, Keizman, Daniel, O’Sullivan, Joe M., Carles, Joan, Wirth, Manfred, Miller, Kurt, Reeves, John, Seger, Monica, Nilsson, Sten, Saad, Fred
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	BioMed Central 2019
Θέματα:	Research Article
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6322274/ https://ncbi.nlm.nih.gov/pubmed/30612558 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-5203-y
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Παρόμοια τεκμήρια